Skip to Content

Dapsone Topical Dosage

Applies to the following strength(s): 5%

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Acne

Apply a pea-size amount topically to affected area twice a day. Gently wash and pat area dry prior to application. Completely rub into skin in a gentle manner.

Usual Pediatric Dose for Acne

12 to 18 years:

Apply a pea-size amount topically to affected area twice a day. Gently wash and pat area dry prior to application. Completely rub into skin in a gentle manner.

Renal Dose Adjustments

No data available

Liver Dose Adjustments

No data available


Dapsone-induced hemolytic anemia and hyperbilirubinemia with oral dapsone therapy are reported to be more likely in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. An initial glucose-6-phosphate dehydrogenase (G6PD) level should be obtained from all patients prior to initiating therapy with dapsone topical.

The manufacturer recommends consideration of other acne therapies for patients with a history of anemia and predisposition to increased hemolytic effect (such as, G6PD deficiency). If other therapies are not feasible, a baseline complete blood count, including a reticulocyte count, should be obtained prior to initiating dapsone topical and repeated on a routine basis in this patient population.

Dapsone topical should be discontinued if signs, symptoms, or laboratory evidence of anemia develops during treatment.

Hemolysis is the most common side effect reported in patients, with or without G6PD deficiency, receiving oral dapsone therapy. Hemolysis may be exaggerated in patients with G6PD deficiency, methemoglobin reductase deficiency, or hemoglobin M. Individuals with G6PD deficiency are more prone to hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern, and Mediterranean ancestry. There was no evidence of clinically relevant hemolysis or anemia in patients treated with dapsone topical, including patients who were G6PD deficient. Some patients with G6PD deficiency using dapsone topical developed laboratory changes suggestive of mild hemolysis. If signs and symptoms suggestive of hemolytic anemia are observed, dapsone topical should be discontinued.

Safety has not been fully evaluated in patients with G6PD deficiency.

Peripheral neuropathy (motor loss and muscle weakness) has been observed with oral dapsone treatment. No events of peripheral neuropathy were noted in clinical trials with topical dapsone topical treatment.

Although not reported with topical dapsone, serious side effects have been reported with oral dapsone therapy including agranulocytosis, hemolytic anemia, peripheral neuropathy (motor loss and muscle weakness), and skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria).

In clinical trials depression and psychosis were reported in patients treated with topical dapsone.

Dapsone gel is for topical use only. It is not for oral, intravaginal, or ophthalmic application.

Dapsone topical has been associated with a 0.32 g/dL drop in hemoglobin during a clinical trial. The hemoglobin levels generally returned to baseline levels at week 12. There was no evidence of clinically significant hemolytic anemia observed in this study. Some of these patients developed laboratory changes suggestive of mild hemolysis.

Safety and effectiveness have not been established in pediatric patients less than 12 years of age.


No data available

Other Comments

The appropriateness and efficacy of treatment with dapsone topical should be reassessed if there is no improvement after 12 weeks of use.

Wash hands immediately after application.